Takeda Announces Early Results of the Previously Announced Cash Tender Offers for Certain Outstanding Notes
July 11, 2024
Test article for UAT
Title goes here
Leadership
Frequently Asked Questions
September 9, 2005
Topic
130 min read
Topic
September 9, 2005
November 30, 2005
Topic
7 min read
Topic
November 30, 2005
This is an H2 header section for the page
This is an H3 for the page
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque. Integer luctus dolor vel justo volutpat consequat. Fusce varius vestibulum metus, eget efficitur elit pretium et. Nulla mauris turpis, euismod nec vehicula vel, condimentum in justo. Praesent aliquet arcu id metus vehicula, eu pharetra orci volutpat. Maecenas consectetur ex et lobortis interdum. Donec a convallis arcu, eu imperdiet turpis. Integer at eros posuere, volutpat lorem vel, laoreet ex. Aenean feugiat velit volutpat lorem imperdiet placerat. Nunc non ultrices diam. Curabitur fermentum neque vel velit commodo.
This is an H4 for the page
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque. Integer luctus dolor vel justo volutpat consequat. Fusce varius vestibulum metus, eget efficitur elit pretium et. Nulla mauris turpis, euismod nec vehicula vel, condimentum in justo. Praesent aliquet arcu id metus vehicula, eu pharetra orci volutpat. Maecenas consectetur ex et lobortis interdum. Donec a convallis arcu, eu imperdiet turpis. Integer at eros posuere, volutpat lorem vel, laoreet ex. Aenean feugiat velit volutpat lorem imperdiet placerat. Nunc non ultrices diam. Curabitur fermentum neque vel velit commodo.
This is an H5 for this page
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque. Integer luctus dolor vel justo volutpat consequat. Fusce varius vestibulum metus, eget efficitur elit pretium et. Nulla mauris turpis, euismod nec vehicula vel, condimentum in justo. Praesent aliquet arcu id metus vehicula, eu pharetra orci volutpat. Maecenas consectetur ex et lobortis interdum. Donec a convallis arcu, eu imperdiet turpis. Integer at eros posuere, volutpat lorem vel, laoreet ex. Aenean feugiat velit volutpat lorem imperdiet placerat. Nunc non ultrices diam. Curabitur fermentum neque vel velit commodo. Donec tristique sit amet libero eget consequat. Maecenas turpis sapien, gravida ac aliquam eu, commodo nec risus. In at tempus ligula. Ut congue hendrerit vehicula. Donec quam nulla, accumsan nec ligula nec, pellentesque tempor justo. Vestibulum faucibus porta justo, ultrices tincidunt tortor mollis quis. Praesent vitae justo id lacus placerat cursus. Nam ut interdum ipsum, nec maximus ex. Ut tempus quam vitae odio tincidunt ultricies. Mauris at quam ac neque finibus fermentum sit amet vitae elit. Etiam tristique, mauris et finibus laoreet, diam metus lacinia urna, sed facilisis nulla.
Innovative. Outstanding. Robust.
R&D
We translate science into highly innovative, life-changing medicines with a research engine that drives diverse, next-generation technologies.
FIND OUT MORE
Join Us
Work with globally diverse colleagues who are committed to bringing Better Health to people and a Brighter Future to the world.
FIND OUT MORE
Investors
Discover Takeda’s balanced, diverse portfolio and strategy for sustainable, patient-centred and resilient growth
FIND OUT MORE
R&D Process
Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque.
Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque.
Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque.
Innovative. Outstanding. Robust.
Lorem ipsum dolor sit amet, consectetur adipiscing elit
December 25, 2022
Lorem ipsum dolor sit amet, consectetur adipiscing elit
December 25, 2022
Lorem ipsum dolor sit amet, consectetur adipiscing elit
December 25, 2022
Accelerating discovery. Life transforming treatments.
Unleashing the power of data and technology is crucial to our vision to transform the lives of patients. Data and technology are revolutionizing our industry and creating better experiences and outcomes for patients by accelerating the discovery, development and delivery of life-transforming treatments. Takeda is on the leading edge of this revolution.
Accelerating discovery. Life transforming treatments.
Unleashing the power of data and technology is crucial to our vision to transform the lives of patients. Data and technology are revolutionizing our industry and creating better experiences and outcomes for patients by accelerating the discovery, development and delivery of life-transforming treatments. Takeda is on the leading edge of this revolution.
Media Contacts
- [email protected]
Japanese Media
- [email protected]
US Media
- 2014565555
Phone
Newsroom Topics Section
Newsroom Topics Section
Newsroom Topics Section
Profile Section
Christophe Weber is president, chief executive officer (CEO) and representative director of Takeda. He joined the company in April 2014 as chief operating officer, was named president and representative director in June 2014, and was subsequently appointed CEO in April 2015. Christophe has focused on ensuring the company’s competitiveness through globalization and R&D transformation - all while creating a diverse and inclusive working environment and strengthening Takeda’s ethical values and corporate governance. Through this transformation, Takeda has become one of the leading global biopharmaceutical companies.
Prior to joining Takeda, Christophe spent 20 years at GlaxoSmithKline where he held senior leadership roles in Europe, Asia and the United States.
Christophe is a member of The US Business Council, the World Economic Forum’s International Business Council, the New York Stock Exchange’s NYSE Board Advisory Council, the Massachusetts Competitive Partnership’s Board of Directors, the MIT CEO Advisory Board and Singapore’s Human Health & Potential International Advisory Committee. He also serves on the Board of Trustees of Northeastern University.
Christophe holds a doctorate in pharmacy and pharmacokinetics, master’s degrees in pharmaceutical marketing and accounting and finance, and a degree in statistics from the University of Lyon, France.
Christophe lives in Tokyo and Boston with his wife and has two children.
Our Focus Areas
Our Focus Areas
Quarterly Result FY2022 (April 2022-March 2023) - Quarter 1
““Our success is due to our 50,000 dedicated and patient-focused colleagues who embody our values.”
““Our success is due to our 50,000 dedicated and patient-focused colleagues who embody our values.”
The Section Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque. Integer luctus dolor vel justo volutpat consequat. Fusce varius vestibulum metus, eget efficitur elit pretium et. Nulla mauris turpis, euismod nec vehicula vel, condimentum in justo. Praesent aliquet arcu id metus vehicula, eu pharetra orci volutpat. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque. Integer luctus dolor vel justo volutpat consequat. Fusce varius vestibulum metus, eget efficitur elit pretium et. Nulla mauris turpis, euismod nec vehicula vel, condimentum in justo. Praesent aliquet arcu id metus vehicula, eu pharetra orci volutpat. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque. Integer luctus dolor vel justo volutpat consequat. Fusce varius vestibulum metus, eget efficitur elit pretium et. Nulla mauris turpis, euismod nec vehicula vel, condimentum in justo. Praesent aliquet arcu id metus vehicula, eu pharetra orci volutpat. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed imperdiet nisl at accumsan pellentesque. Integer varius sem eget tortor imperdiet scelerisque. Integer luctus dolor vel justo volutpat consequat. Fusce varius vestibulum metus, eget efficitur elit pretium et. Nulla mauris turpis, euismod nec vehicula vel, condimentum in justo. Praesent aliquet arcu id metus vehicula, eu pharetra orci volutpat.
1912
Title.
Aenean eros ipsum, interdum quis dignissim non, sollicitudin vitae nisl. Aenean vel aliquet elit, at blandit ipsum.
1922
Title.
Aenean eros ipsum, interdum quis dignissim non, sollicitudin vitae nisl. Aenean vel aliquet elit, at blandit ipsum.
1932
Title.
Aenean eros ipsum, interdum quis dignissim non, sollicitudin vitae nisl. Aenean vel aliquet elit, at blandit ipsum.
1942
Title.
Aenean eros ipsum, interdum quis dignissim non, sollicitudin vitae nisl. Aenean vel aliquet elit, at blandit ipsum.
Image caption
List title
- Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.
- Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
- Sed ut perspiciatis undeomnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.
- Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Related Stories
Takeda to Hold Third Quarter FY2022 Earnings Call on February 2
January 24, 2023
Takeda to Present Multiple New Data Analyses at 2023 AAAAI Annual Meeting, Including SPRING Study of TAKHZYRO<sup>®</sup> (lanadelumab-flyo) in Pediatric Patients With Hereditary Angioedema (HAE)
February 13, 2023
Section title
Section subtitle
Loading...